title: Treatment effects of serotonergic and noradrenergic antidepressants on the intensity dependence of auditory ERP components in major depression.
abstract: The intensity dependent amplitude change of auditory evoked potentials (IDAP), an assumed indicator of the level of central nervous serotonergic neurotransmission, was measured in major depressive disorder (MDD, DSM-IV: 296.2, 296.3; APA 1994) before and after treatment with either a selective serotonin reuptake inhibitor or a selective noradrenaline reuptake inhibitor antidepressant and compared with the results of a healthy control group. Auditory evoked P1, N1, P2, P1/N1 and N1/P2 peak-to-peak amplitudes were evaluated in 26 in-patients with MDD prior to and after antidepressant treatment with citalopram (24 days, n=14) or reboxetine (25 days, n=12), and in 43 healthy control subjects. Clinical symptoms of MDD were assessed by means of standardized psychiatric rating scales (CGI, HDRS, HAMA and BDI). The IDAP within the control group remained stable over 24 days (N1 amplitude slope retest ANOVA p=.79). Neither applied antidepressants nor decrease of HDRS total score during treatment had a significant effect on the IDAP in the patients' sample. The conclusion that the IDAP does not reflect the temporary depressive state in MDD is discussed.
authors.affiliation: Clinic for Psychiatry and Psychotherapy, Rheinische Kliniken Essen, University of Duisburg-Essen, 45147 Essen, Germany. thomas.linka@uni-due.de
authors.forename: Thomas
authors.initials: T
authors.lastname: Linka
authors.forename: Gudrun
authors.initials: G
authors.lastname: Sartory
authors.forename: Jens
authors.initials: J
authors.lastname: Wiltfang
authors.forename: Bernhard W
authors.initials: BW
authors.lastname: Müller
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D015283:Citalopram / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D005072:Evoked Potentials, Auditory / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D015283:Citalopram; D009025:Morpholines; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors